Showing 3811-3820 of 9331 results for "".
- RoC Skincare Marks the First National Retinol Dayhttps://practicaldermatology.com/news/roc-skincare-marks-the-first-national-retinol-day/2460977/Just as Americans set back their clocks this weekend, retinol can help turn back the clock on fine lines and wrinkles. That's the message from RoC® Skincare in honor of the first-ever National Retinol Day on Sunday. National Retinol Day has been registered for annual
- New Image-Guided Dermatology Therapy System Receives CE Mark in Europehttps://practicaldermatology.com/news/new-oncology-and-dermatology-device-approved-europe/2463232/Ultrasound tech manufacturer TOOsonix A/S announced that it has received EU Medical Device Regulation (MDR) CE certification for its image-guided dermatologic therapy system, System ONE-M™, according to a news release from the company. The device facilitates the treatment of common skin c
- Study: Galderma's RelabotulinumtoxinA Earns High Marks from Patientshttps://practicaldermatology.com/news/study-galdermas-relabotulinumtoxina-earns-high-marks-from-patients/2461377/Galderma's investigational ready-to-use liquid botulinum toxin RelabotulinumtoxinA scored high patient satisfaction and psychological well-being ratings for the treatment of glabellar lines and lateral canthal lines in addition to previously reported safety and efficacy, according to pre
- High Kissability Marks for Restylane Kysse in New Phase 4 Studyhttps://practicaldermatology.com/news/high-kissability-marks-for-restylane-kysse-in-new-phase-4-study/2460465/In a recent first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, subject satisfaction as well as partner satisfaction were evaluated following treatment with Restylane Kysse. Many consumers report they often keep their lip treatments a
- Jan Marini Skin Research Marks 20 Years of Innovationhttps://practicaldermatology.com/news/20140625-jan_marini_skin_research_marks_20_years_of_innovation/2459188/After 20 years, Jan Marini Skin Research (JMSR) continues to distinguish itself as a recognized leader in the professional skincare industry through its combined focus on results, new productinnovation and its commitment to clinical and medical validation. Robert Weiss, MD, conducted a st
- Outrun the Sun Marks 10 Years of Sun Safety Education and Melanoma Researchhttps://practicaldermatology.com/news/20140428-outrun_the_sun_marks_10_years_of_sun_safety_education_and_melanoma_research/2459253/Outrun the Sun, Inc. (OTS), a nonprofit organization that has raised more than $1 million in support of skin cancer education and melanoma research, celebrates their 10 year anniversary. OTS was formed by Anita Day, Jonna MacDougall, Marci Reddick and Jennifer Patton Sarno because they h
- Cetaphil® Marks Fifth Year of Support for CSDF and Camp Wonderhttps://practicaldermatology.com/news/cetaphil-marks-fifth-year-of-support-for-csdf-and-camp-wonder/2458452/Galderma Laboratories, L.P., makers of Cetaphil, is celebrating the fifth consecutive year of its "Meaningphil™" partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder.</
- Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn to Treat Mild to Moderate Acnehttps://practicaldermatology.com/news/20140204-oculus_innovative_sciences_receives_european_ce_mark_for_use_of_microcyn_to_treat_mild_to_moderate_acne/2459350/
- Epicutis Launches Arctigenin Brightening Treatmenthttps://practicaldermatology.com/news/epicutis-launches-arctigenin-brightening-treatment/2468350/Epicutis announced that it has launched its Arctigenin Brightening Treatment, marking what the manufacturer called a significant shift in skin br
- ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Awardhttps://practicaldermatology.com/news/zoryve-wins-2025-allure-best-of-beauty-breakthrough-award/2483410/Arcutis Biotherapeutics’ ZORYVE® (roflumilast) was the recipient of Allure magazine’s 2025 Best of Beauty Breakthrough Award, marking the first time a prescription topical for atopic dermatitis (AD), plaque psoriasis, and seborrheic dermatitis has received the accol